Biologics Market Size, Share, Industry Demand, Growth and Analysis for Forecast 2024 to 2029
The global biologics market is set to witness a growth rate of 10-12% in the next 5 years. Rising prevalence of chronic diseases; continued advancements in biotechnology; growing investment in biopharmaceutical R&D; and growing strategic partnerships between biotech firms & larger pharmaceutical companies are some of the key factors driving the biologics market. To learn more about the research report, download a sample report.
Biologics are a class of medications derived from living organisms, including proteins, sugars, and nucleic acids among others. They encompass a wide range of products such as vaccines, monoclonal antibodies, and gene therapies, which are often used to treat complex diseases like cancer and autoimmune disorders. Unlike traditional drugs, which are chemically synthesized, biologics are typically large, complex molecules that cannot be easily characterized. Their production involves biological processes and requires stringent quality control to ensure consistency and efficacy across batches. As advanced therapeutics, biologics represent a significant area of innovation in modern medicine.
To learn more about this report, download the PDF brochure
Rising prevalence of chronic diseases to propel market demand
The rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, is significantly driving the biologics market. Biologics, including monoclonal antibodies, vaccines, and gene therapies, offer targeted, effective treatments for these complex conditions. As chronic diseases continue to increase globally due to aging populations and lifestyle factors, the demand for advanced therapies like biologics has surged. Biologics provide enhanced efficacy, reduced side effects, and personalized treatment options, making them critical in addressing the growing burden of chronic diseases. This trend is pushing pharmaceutical companies to invest heavily in biologic drug development and innovation.
Growing investment in biopharmaceutical R&D driving the market growth
Growing investment in biopharmaceutical R&D is a key driver of the biologics market. Pharmaceutical companies are increasingly allocating resources to develop innovative biologic therapies, recognizing their potential to treat complex diseases effectively. This surge in investment supports advancements in biotechnology, leading to the discovery of novel biologics, including monoclonal antibodies and cell therapies. Additionally, collaborations between academia, industry, and government institutions foster a conducive environment for R&D, accelerating the pipeline of biologic products. As a result, the increased focus on biopharmaceutical R&D is propelling market growth by expanding treatment options and enhancing patient outcomes.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global biologics market is marked by the presence of established and emerging market players such as AbbVie Inc., Amgen Inc., Biogen, Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Samsung BioLogics and Sanofi; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Biologics Market Scope
|
Report Scope |
Details |
|
Base Year Considered |
2023 |
|
Historical Data |
2022 - 2023 |
|
Forecast Period |
2024 - 2029 |
|
Growth Rate |
CAGR 10-12% |
|
Segment Scope |
Product, Modality, Type, Manufacturing, Indication |
|
Regional Scope |
|
|
Key Companies Mapped |
AbbVie Inc., Amgen Inc., Biogen, Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Samsung BioLogics and Sanofi; among others |
|
Report Highlights |
Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Key Strategic Questions Addressed
-
What is the market size & forecast of the biologics market?
-
What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the biologics market?
-
What are the key trends defining the market?
-
What are the major factors impacting the market?
-
What are the opportunities prevailing in the market?
-
Which region has the highest share in the global market?
-
Which region is expected to witness the highest growth rate in the next 5 years?
-
Who are the major players operating in the market?
-
What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2023-2024)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Biologics Market Snapshot (2023-2029)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Rising prevalence of chronic diseases
- Continued advancements in biotechnology
- Growing investment in biopharmaceutical R&D
- Growing strategic partnerships between biotech & larger pharmaceutical companies
- Restraints
- High production costs
- Stringent regulatory requirements
- Competition from small molecule drugs and generics
- Opportunities
- Personalized medicine
- Biosimilars
- Emerging therapeutic applications
- Key Market Trends
- Advanced biomanufacturing technologies
- Cell and gene therapies
- Unmet Market Needs
- Industry Speaks
- Pipeline Analysis
- Regulatory Analysis
- Drivers
- Market Dynamics
- Global Biologics Market Size & Forecast (2022-2029), By Product, USD Million
- Introduction
- Keytruda
- Comirnaty
- Humira
- Eylea
- Dupixent
- Stelara
- Opdivo
- Ocrevus
- Rituxan
- Xolair
- Others
- Global Biologics Market Size & Forecast (2022-2029), By Modality, USD Million
- Introduction
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Cell and Gene Therapies
- Others
- Global Biologics Market Size & Forecast (2022-2029), By Type, USD Million
- Introduction
- Innovative
- Generic/Biosimilars
- Biologics Market Size & Forecast (2022-2029), By Manufacturing, USD Million
- Introduction
- In-house/Captive Manufacturing
- Outsourced/Merchant Manufacturing
- Others
- Biologics Market Size & Forecast (2022-2029), By Indication, USD Million
- Introduction
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Respiratory Disorders
- Others
- Global Biologics Market Size & Forecast (2022-2029), By Region, USD Million
- Introduction
- North America Biologics Market Size & Forecast (2022-2029), By Country, USD Million
- US
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Canada
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- US
- Europe Biologics Market Size & Forecast (2022-2029), By Country, USD Million
- UK
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Germany
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- France
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Italy
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Spain
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Rest of Europe
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- UK
- Asia Pacific (APAC) Biologics Market Size & Forecast (2022-2029), By Country, USD Million
- China
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Japan
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- India
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
- China
- Latin America (LATAM) Biologics Market Size & Forecast (2022-2029), USD Million
-
-
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
-
- Middle East & Africa (MEA) Biologics Market Size & Forecast (2022-2029), USD Million
-
-
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Modality (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By Manufacturing (USD Million)
- Market Size & Forecast, By Indication (USD Million)
-
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2023)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2024)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Sanofi
- Other Prominent Players
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Healthcare Providers, Researchers, Doctors, Physicians, Specialists, Oncologist, Pharmacists and others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
